Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.
The FDA has accepted Roche's new drug application for giredestrant plus everolimus to treat ER-positive, HER2-negative, ESR1-mutated advanced breast cancer following prior endocrine therapy, with a decision expected by December 18, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06590857 |
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06439693 |
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer |
RECRUITING | PHASE2 |
| NCT02957968 |
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01953588 |
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01791478 |
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer |
COMPLETED | PHASE1 |
